Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2013
   Guideline
2. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011
   Guideline
3. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors.Pancreas · 2015
   Trial
4. Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors.Endocrine-related cancer · 2025
   Review
5. Non-functional, non-mutated multifocal neuroendocrine neoplasms in a postpartum female: a Case Report of an infrequent disease.Frontiers in medicine · 2025
   Article
6. Systemic Therapy for Pancreatic Neuroendocrine Tumors.Indian journal of surgical oncology · 2024
   Review
7. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3World journal of gastroenterology · 2021
   Article
8. Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report.BMC research notes · 2013
   Article
9. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011
   Article

Corrections and comments

• Erratum for
  Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.2017

Authors and funding

9 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.